|Day's range||4.5000 - 4.5000|
Mylan (MYL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Investors will look forward to regular top and bottom-line numbers and updates on the merger with Upjohn, when Mylan (MYL) reports Q2 results.
Mylan (MYL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Drugmaker Mylan NV <MYL.O> said on Wednesday it has received Indian regulatory approval to make tuberculosis treatment pretomanid available in a country that accounts for a quarter of the world's cases. Mylan will initially make a donation of 400 treatment courses of pretomanid under the Indian government's National Tuberculosis Elimination Program (NTEP) and will provide commercial access at $364 for a six-month treatment course. "The Drug Controller General of India has approved the anti-tuberculosis drug pretomanid for conditional access under the NTEP," Mylan said in an emailed statement.
Today, Delaware Enhanced Global Dividend and Income Fund (the "Fund"), a New York Stock Exchange–listed closed-end fund trading under the symbol "DEX," declares a monthly distribution of $0.0499 per share. The monthly distribution is payable July 24, 2020, to shareholders of record at the close of business on July 17, 2020. The ex-dividend date will be July 16, 2020.
Mylan NV <MYL.O> said on Monday it would launch a generic version of Gilead Sciences Inc's <GILD.O> COVID-19 antiviral remdesivir in India at 4,800 rupees ($64.31), about 80% below the price tag on the drug for wealthy nations. California-based Gilead has signed licensing deals with several generic drugmakers in an effort to make remdesivir available in 127 developing countries. Last month, two Indian drugmakers, Cipla Ltd <CIPL.NS> and privately-held Hetero Labs Ltd, also launched generic versions of the treatment.
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Mylan N.V. (NASDAQ: MYL) between February 16, 2016 and May 7, 2019, inclusive (the "Class Period"), of the important August 25, 2020 lead plaintiff deadline in securities class action. The lawsuit seeks to recover damages for Mylan investors under the federal securities laws.
Every investor in Mylan, Inc. (NASDAQ:MYL) should be aware of the most powerful shareholder groups. Insiders often own...
Biogen (NASDAQ: BIIB) shares slid 12.9% in June, according to data provided by S&P Global Market Intelligence, as the company lost a patent ruling on its blockbuster multiple sclerosis (MS) drug. In a challenge involving rival Mylan, a federal court in West Virginia invalidated Biogen's Tecfidera patent. The decision clears the way for rival Mylan to bring a generic competitor to market.
Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Mylan N.V. ("Mylan" or the "Company") (NASDAQ: MYL) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Mylan securities between February 16, 2016 and May 7, 2019, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm’s site: www.bgandg.com/myl.
SHAREHOLDER ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Mylan N.V.
SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Mylan N.V.
Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Mylan N.V. (NASDAQ: MYL) between February 16, 2016 and May 7, 2019, inclusive (the "Class Period"). The lawsuit seeks to recover damages for Mylan investors under the federal securities laws.
On June 26, 2020, Delaware Enhanced Global Dividend and Income Fund (NYSE: DEX) (the "Fund"), a closed-end fund, paid a monthly distribution on its common stock of $0.0485 per share to shareholders of record at the close of business on June 19, 2020.
The U.S. District Court of West Virginia gives a ruling against Biogen (BIIB) over a patent dispute with generic drugmaker Mylan pertaining to its best-selling multiple sclerosis drug, Tecfidera.
Tecfidera has been Biogen's main growth driver since it was launched in 2013, generating sales of $4.43 billion in 2019, accounting for nearly a third of total revenue. A court in the Northern District of West Virginia ruled Mylan had established that the asserted claims of Biogen's patent were invalid. The '514 patent provided exclusivity into 2028 and with another Biogen patent set to expire on Friday, the ruling creates a significant issue for the company to contend with, Wedbush analyst Laura Chico said.
Upjohn Inc. ("Newco"), a wholly-owned subsidiary of Pfizer Inc. ("Pfizer") (NYSE: PFE), Upjohn Finance B.V. ("Finco"), a wholly-owned subsidiary of Newco, Pfizer and Mylan N.V. ("Mylan") (Nasdaq: MYL) today announced the pricing of a private offering of $7.45 billion aggregate principal amount of Newco’s senior, U.S. dollar-denominated notes (collectively, the "U.S. Dollar Notes") and a private offering of €3.60 billion aggregate principal amount of Finco’s senior, euro-denominated notes (collectively, the "Euro Notes" and, together with the U.S. Dollar Notes, the "Notes"), comprised of:
The FDA said that chloroquine and hydroxychloroquine are unlikely to prove effective in treating COVID-19 as the known benefits outweigh the risks.
FDA approves Glaxo's (GSK) oral suspension formulation of its three-drug regimen for HIV, Tivicay, as a treatment for patients aged at least four weeks and weighing at least 3kg.
Here's some welcome news for diabetics dealing with the high price of insulin: The Food and Drug Administration has approved Mylan (NASDAQ: MYL) and Biocon's Semglee, which is essentially identical to Sanofi's (NASDAQ: SNY) insulin product Lantus. The companies didn't disclose what they plan to charge for Semglee when announcing the approval, but Mylan CEO Heather Bresch implied that it would be cheaper than Lantus. The opportunity for Mylan and Biocon (which bills itself as India's largest biopharmaceutical) is substantial; IQVIA estimates that Sanofi took in $1.68 billion in revenue from Lantus vials and $4.33 billion from the Lantus SoloSTAR Pen in the 12-month period that ended in April.